Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma

Recurrent and persistent head and neck squamous cell carcinoma is becoming an increasingly important cohort for head and neck cancer providers. While curative treatment is achieved in many instances, approximately 25 –50% of patients with head and neck squamous cell carcinoma will experience recurrence, and the overall median survival for those with recurrent disease who undergo treatment is less than 22 months [1]. Treatment for recurrence tends to be difficult, as these tumors are often resistant to standa rd therapy, complication rates are higher, and prognosis is guarded [2].

Source: Oral Oncology - December 25, 2017 Category: Cancer & Oncology Authors: Rebecca Hoesli, Andrew C. Birkeland, Andrew J. Rosko, Mohamad Issa, Kelsey L. Chow, Nicole L. Michmerhuizen, Jacqueline E. Mann, Steven B. Chinn, Andrew G. Shuman, Mark E. Prince, Gregory T. Wolf, Carol R. Bradford, Jonathan B. McHugh, J. Chad Brenner, Ma Source Type: research